CIA
CSTL icon

Capital Impact Advisors’s Castle Biosciences CSTL Stock Holding History

Capital Impact Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,713
Closed -$503K – 64
2024
Q1 		$503K Buy
22,713
+6,159
+37% +$134K 0.65% 67
2023
Q4 		$357K Hold
16,554
– – 0.47% 81
2023
Q3 		$280K Hold
16,554
– – 0.47% 88
2023
Q2 		$227K Buy
16,554
+1,102
+7% +$22.3K 0.25% 152
2023
Q1 		$351K Hold
15,452
– – 0.43% 111
2022
Q4 		$364K Buy
15,452
+997
+7% +$23.1K 0.36% 123
2022
Q3 		$289K Buy
14,455
+485
+3% +$13.6K 0.29% 143
2022
Q2 		$307K Sell
13,970
-3,561
-20% -$82.7K 0.28% 153
2022
Q1 		$786K Sell
17,531
-6,898
-28% -$285K 0.57% 72
2021
Q4 		$1.05M Buy
24,429
+7,726
+46% +$404K 0.72% 53
2021
Q3 		$1.11M Buy
16,703
+3,500
+27% +$246K 0.44% 95
2021
Q2 		$968K Buy
13,203
+11,172
+550% +$738K 0.31% 111
2021
Q1 		$139K Sell
2,031
-22,969
-92% -$1.73M 0.05% 108
2020
Q4 		$1.68M Buy
+25,000
New +$1.36M 0.41% 91

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Capital Impact Advisors's CSTL Position: Q2 2024 in Review

Capital Impact Advisors sold out of Castle Biosciences (CSTL) in Q2 2024, closing a stake of 22,713 shares — an estimated $503K sold.

Capital Impact Advisors first reported a position in CSTL in Q4 2020 and held it in 14 quarters. The position peaked at $1.68M in Q4 2020. 159 funds tracked by Wall St. Rank hold CSTL as of Q2 2024.

  • Capital Impact Advisors reported no remaining Castle Biosciences position as of Q2 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 22,713 Castle Biosciences shares in Q2 2024, an estimated $503K.
  • Capital Impact Advisors first reported a position in Castle Biosciences in Q4 2020 and held it in 14 quarters.
  • Capital Impact Advisors's Castle Biosciences position peaked at $1.68M in Q4 2020.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.